{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [],
   "source": [
    "#  解析 EMA 数据库\n",
    "import json\n",
    "\n",
    "with open('./EMA_drug_name_indication.txt','r') as file, open('./ema_database.json','w') as fl:\n",
    "    file.seek(0,0)\n",
    "    for line in file:\n",
    "        res = {}\n",
    "        drug_name = line.strip().split(\"\\t\")[0].lower()\n",
    "#        indication = [line.split(\"\\t\")[1].lower()]\n",
    "        Drug_name = line.strip().split(\"\\t\")[0]\n",
    "        indication = line.replace(Drug_name,\"\").replace('\"','').replace(\".,\",\".\").replace(\" ,\",\"\").replace(\",,\",\",\").replace(\"\\t\",\"\").strip().lower()\n",
    "        res[\"drug_name\"] = drug_name\n",
    "        res[\"indication\"] = indication\n",
    "        res[\"phase\"] = \"\"\n",
    "        res[\"recruitment_status\"] = \"\"\n",
    "        res[\"company\"] = \"\"\n",
    "        res[\"2014_sales\"] = \"\"\n",
    "        res[\"2015_sales\"] = \"\"\n",
    "        res[\"2016_sales\"] = \"\"\n",
    "        res[\"2017_sales\"] = \"\"\n",
    "        res[\"2018_sales\"] = \"\"\n",
    "        res[\"sales_unit\"] = \"million usd\"\n",
    "        res[\"source\"] = [\"ema\"]\n",
    "        fl.write(json.dumps(res) + \"\\n\")\n",
    "        \n",
    "        \n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "with open('./all_database.json','r') as file, open('./fda_kegg_sider_drugbank_ttd_database.json','w') as fl:\n",
    "    file.seek(0,0)\n",
    "    for line in file:\n",
    "        line_dict = json.loads(line.strip())\n",
    "        data_source = line_dict[\"data_source\"]\n",
    "        if (data_source == \"fda\") or (data_source == \"kegg\") or (data_source == \"sider\") or \\\n",
    "            (data_source == \"drug_bank\") or (data_source == \"ttd\"):\n",
    "        \n",
    "            indication_list_new = []\n",
    "            drug_name = line_dict[\"drug_name\"].strip().lower()\n",
    "            indication_list = line_dict[\"indication\"]\n",
    "        \n",
    "            for indication in indication_list:\n",
    "                indication_lower = indication.strip().lower()\n",
    "                indication_list_new.append(indication_lower)        \n",
    "            \n",
    "            for indication in indication_list_new:\n",
    "                res = {}\n",
    "                res[\"drug_name\"] = drug_name\n",
    "                res[\"indication\"] = indication.lower().strip()\n",
    "                res[\"phase\"] = \"\"\n",
    "                res[\"recruitment_status\"] = \"\"\n",
    "                res[\"company\"] = \"\"\n",
    "                res[\"2014_sales\"] = \"\"\n",
    "                res[\"2015_sales\"] = \"\"\n",
    "                res[\"2016_sales\"] = \"\"\n",
    "                res[\"2017_sales\"] = \"\"\n",
    "                res[\"2018_sales\"] = \"\"\n",
    "                res[\"sales_unit\"] = \"million usd\"\n",
    "                res[\"source\"] = [data_source]\n",
    "                fl.write(json.dumps(res) + \"\\n\")\n",
    "            \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [],
   "source": [
    "#   drugananyst 数据库\n",
    "import json\n",
    "\n",
    "with open('./drugananyst.txt','r') as file, open('./drugananyst_database.json','w') as fl:\n",
    "    file.seek(0,0)\n",
    "    num = 0\n",
    "    for line in file:\n",
    "        num = num + 1\n",
    "#        print(num)\n",
    "\n",
    "        drug_name = line.strip().split(\"\\t\")[0].lower()\n",
    "        indication_list = line.strip().split(\"\\t\")[1].split(\"/\")    # 是个用“/”分隔的 list\n",
    "        company = line.strip().split(\"\\t\")[2].lower()\n",
    "        sales_2017 = line.split(\"\\t\")[3].lower()\n",
    "        sales_2018 = line.split(\"\\t\")[4].replace(\"\\n\",\"\").lower()\n",
    "        \n",
    "        for indication in indication_list:\n",
    "            res = {}\n",
    "            res[\"drug_name\"] = drug_name\n",
    "            res[\"indication\"] = indication.lower().strip()\n",
    "            res[\"phase\"] = \"\"\n",
    "            res[\"recruitment_status\"] = \"\"\n",
    "            res[\"company\"] = company\n",
    "            res[\"2014_sales\"] = \"\"\n",
    "            res[\"2015_sales\"] = \"\"\n",
    "            res[\"2016_sales\"] = \"\"\n",
    "            res[\"2017_sales\"] = sales_2017\n",
    "            res[\"2018_sales\"] = sales_2018\n",
    "            res[\"sales_unit\"] = \"million usd\"\n",
    "            res[\"source\"] = [\"drugananyst\"]\n",
    "            fl.write(json.dumps(res) + \"\\n\")\n",
    "        \n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [],
   "source": [
    "#   clinicaltrails 数据库\n",
    "import json\n",
    "\n",
    "with open('./clinicaltrails.json','r') as file, open('./clinicaltrails_database.json','w') as fl:\n",
    "    file.seek(0,0)\n",
    "    for line in file:\n",
    "        line_dict = json.loads(line.strip())\n",
    "        drug_name_list = line_dict[\"Intervention\"]\n",
    "        indication_list = line_dict[\"Condition\"].strip().split(\"\\n\")\n",
    "        phase = line_dict[\"Study Phase\"]\n",
    "        if phase:\n",
    "            phase = phase.lower()\n",
    "        else:\n",
    "            phase = \"\"\n",
    "        recruitment_status = line_dict[\"Recruitment Status\"].lower().strip()\n",
    "        \n",
    "        res = {}\n",
    "        res[\"phase\"] = phase\n",
    "        res[\"recruitment_status\"] = recruitment_status\n",
    "        res[\"company\"] = \"\"\n",
    "        res[\"2014_sales\"] = \"\"\n",
    "        res[\"2015_sales\"] = \"\"\n",
    "        res[\"2016_sales\"] = \"\"\n",
    "        res[\"2017_sales\"] = \"\"\n",
    "        res[\"2018_sales\"] = \"\"\n",
    "        res[\"sales_unit\"] = \"million usd\"\n",
    "        res[\"source\"] = [\"clinicaltrails\"]\n",
    "        for drug_name in drug_name_list:\n",
    "            for indication in indication_list:                \n",
    "                res[\"drug_name\"] = drug_name.lower().strip()\n",
    "                res[\"indication\"] = indication.lower().strip()\n",
    "\n",
    "                fl.write(json.dumps(res) + \"\\n\")\n",
    "            \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [],
   "source": [
    "#  pharmcube  医药魔方数据库\n",
    "\n",
    "import json\n",
    "with open('./pharmcube.txt','r') as file, open('./pharmcube_database.json','w') as fl:\n",
    "    \n",
    "    dict_qu = {}\n",
    "    file.seek(0,0)\n",
    "    for line in file:\n",
    "        line_list = line.strip().split(\"\\t\")\n",
    "        drug_name = line_list[0].strip().lower()\n",
    "        company_name = line_list[1].strip().lower()\n",
    "        sales_2014 = line_list[2].strip().lower()\n",
    "        if sales_2014 == \"--\":\n",
    "            sales_2014 = \"\"\n",
    "        sales_2015 = line_list[3].strip().lower()\n",
    "        if sales_2015 == \"--\":\n",
    "            sales_2015 = \"\"\n",
    "        sales_2016 = line_list[4].strip().lower()\n",
    "        if sales_2016 == \"--\":\n",
    "            sales_2016 = \"\"\n",
    "        sales_2017 = line_list[5].strip().lower()\n",
    "        if sales_2017 == \"--\":\n",
    "            sales_2017 = \"\"\n",
    "        sales_2018 = line_list[6].strip().lower()\n",
    "        if sales_2018 == \"--\":\n",
    "            sales_2018 = \"\"\n",
    "        \n",
    "        res = {}\n",
    "        res[\"drug_name\"] = drug_name\n",
    "        res[\"indication\"] = \"\"\n",
    "        res[\"phase\"] = \"\"\n",
    "        res[\"recruitment_status\"] = \"\"\n",
    "        res[\"company\"] = company_name\n",
    "        res[\"2014_sales\"] = sales_2014\n",
    "        res[\"2015_sales\"] = sales_2015\n",
    "        res[\"2016_sales\"] = sales_2016\n",
    "        res[\"2017_sales\"] = sales_2017\n",
    "        res[\"2018_sales\"] = sales_2018\n",
    "        res[\"sales_unit\"] = \"million \" + line_list[7].strip().lower()\n",
    "        res[\"source\"] = \"pharmcube\"\n",
    "        res[\"phase_front_display\"] = \"\"\n",
    "        dict_qu[json.dumps(res)] = 1\n",
    "    for key in dict_qu:\n",
    "        fl.write(key + \"\\n\")\n",
    "        \n",
    "        \n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "word = \"  \\n                           \\n                           \\n                           \\n                         \"\n",
    "word_list = word.strip()\n",
    "print(word_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "#  将两个库中的数据合在一个文件里\n",
    "with open('./clinicaltrails_database.json', mode='r') as file, open('./all_eight_database.json', 'a') as fl:\n",
    "        \n",
    "        file.seek(0,0)\n",
    "        line = file.readline()\n",
    "        \n",
    "        while(line):\n",
    "            line_dict = json.loads(line.strip())        \n",
    "            fl.write(json.dumps(line_dict) + '\\n')\n",
    "            \n",
    "            line = file.readline()\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [],
   "source": [
    "#  做归一、去重处理\n",
    "import json\n",
    "import pickle\n",
    "\n",
    "with open('./medical_entity_dict_v5.0.pkl','rb') as file:\n",
    "    med_synonyms_name_dict, med_name_cate_dict = pickle.loads(file.read())\n",
    "\n",
    "with open('./all_eight_database.json','r') as file, open('./all_eight_database_after_guiyi_quchong.json','w') as fl:\n",
    "    file.seek(0,0)\n",
    "    \n",
    "    dict_qu = {}\n",
    "    drug_name_in_dict = 0\n",
    "    for line in file:\n",
    "        line_dict = json.loads(line.strip())\n",
    "        drug_name = line_dict[\"drug_name\"]\n",
    "        phase = line_dict[\"phase\"]\n",
    "        \n",
    "        if drug_name in med_synonyms_name_dict:\n",
    "            drug_name_in_dict += 1\n",
    "            line_dict[\"drug_name\"] = med_synonyms_name_dict[drug_name]\n",
    "        if \"phase 4\" in phase:\n",
    "            phase_front_display = \"approved\"\n",
    "        else:\n",
    "            phase_front_display = phase\n",
    "        \n",
    "        line_dict[\"phase_front_display\"] = phase_front_display    \n",
    "        dict_qu[json.dumps(line_dict)] = 1\n",
    "    for key in dict_qu:\n",
    "        fl.write(key + \"\\n\")\n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "359823\n"
     ]
    }
   ],
   "source": [
    "print(drug_name_in_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [],
   "source": [
    "#  提取 all_eight_database_after_guiyi_quchong.json 中所有的药物名称\n",
    "\n",
    "import json\n",
    "\n",
    "with open('./all_eight_database_after_guiyi_quchong.json','r') as file, \\\n",
    "    open('./drug_name_list.txt','w') as fl:\n",
    "#    drug_name_list = []\n",
    "    file.seek(0,0)\n",
    "    for line in file:\n",
    "        line_dict = json.loads(line.strip())\n",
    "        drug_name = line_dict[\"drug_name\"]\n",
    "        fl.write(drug_name + \"\\n\")\n",
    "    \n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'drug_name': 'lucentis', 'indication': 'opthalmic (amd', 'phase': '', 'recruitment_status': '', 'company': 'novartis', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '1,888', '2018_sales': '2,046', 'sales_unit': 'million usd', 'source': ['drugananyst'], 'phase_front_display': ''}, {'drug_name': 'lucentis', 'indication': 'rvo', 'phase': '', 'recruitment_status': '', 'company': 'novartis', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '1,888', '2018_sales': '2,046', 'sales_unit': 'million usd', 'source': ['drugananyst'], 'phase_front_display': ''}, {'drug_name': 'lucentis', 'indication': 'dme)', 'phase': '', 'recruitment_status': '', 'company': 'novartis', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '1,888', '2018_sales': '2,046', 'sales_unit': 'million usd', 'source': ['drugananyst'], 'phase_front_display': ''}]\n",
      "{\"drug_name\": \"lucentis\", \"indication\": \"\", \"phase\": \"\", \"recruitment_status\": \"\", \"company\": \"novartis\", \"2014_sales\": \"2441\", \"2015_sales\": \"2060\", \"2016_sales\": \"1835\", \"2017_sales\": \"1888\", \"2018_sales\": \"2046\", \"sales_unit\": \"million usd\", \"source\": \"pharmcube\", \"phase_front_display\": \"\"}\n",
      "[{'drug_name': 'seebri breezhaler', 'indication': 'asthma', 'phase': '', 'recruitment_status': '', 'company': 'novartis', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '151', '2018_sales': '148', 'sales_unit': 'million usd', 'source': ['drugananyst'], 'phase_front_display': ''}, {'drug_name': 'seebri breezhaler', 'indication': 'copd', 'phase': '', 'recruitment_status': '', 'company': 'novartis', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '151', '2018_sales': '148', 'sales_unit': 'million usd', 'source': ['drugananyst'], 'phase_front_display': ''}]\n",
      "{\"drug_name\": \"seebri breezhaler\", \"indication\": \"\", \"phase\": \"\", \"recruitment_status\": \"\", \"company\": \"novartis\", \"2014_sales\": \"146\", \"2015_sales\": \"150\", \"2016_sales\": \"149\", \"2017_sales\": \"151\", \"2018_sales\": \"\", \"sales_unit\": \"million usd\", \"source\": \"pharmcube\", \"phase_front_display\": \"\"}\n",
      "[{'drug_name': 'ultibro breezhaler', 'indication': 'asthma', 'phase': '', 'recruitment_status': '', 'company': 'novartis', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '411', '2018_sales': '454', 'sales_unit': 'million usd', 'source': ['drugananyst'], 'phase_front_display': ''}, {'drug_name': 'ultibro breezhaler', 'indication': 'copd', 'phase': '', 'recruitment_status': '', 'company': 'novartis', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '411', '2018_sales': '454', 'sales_unit': 'million usd', 'source': ['drugananyst'], 'phase_front_display': ''}]\n",
      "{\"drug_name\": \"ultibro breezhaler\", \"indication\": \"\", \"phase\": \"\", \"recruitment_status\": \"\", \"company\": \"novartis\", \"2014_sales\": \"118\", \"2015_sales\": \"260\", \"2016_sales\": \"363\", \"2017_sales\": \"411\", \"2018_sales\": \"\", \"sales_unit\": \"million usd\", \"source\": \"pharmcube\", \"phase_front_display\": \"\"}\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "with open('./all_eight_database_after_guiyi_quchong.json','r') as file, \\\n",
    "    open('./pharmcube_database.json','r') as fl, \\\n",
    "    open('./all_eight_database_after_combine.json','a') as fw1, \\\n",
    "    open('./all_eight_database_todo_data_menghe.json','a') as fw2:\n",
    "    \n",
    "    drug_name_indication_dict = {}   #  将一个 drug_name 对应的所有 indication 都提取出来\n",
    "    drug_name_company_set = set()        #  将 drug_name、company 的结合字符串存在一个集合里\n",
    "    drugname_company_sales_unit_dict = {}   #  将 drug_name、company、sales_unit 的结合字符串作为 key,整条 line_dict 作为 value\n",
    "    \n",
    "    file.seek(0,0)\n",
    "    for line in file:\n",
    "        line_dict = json.loads(line.strip())\n",
    "        drug_name = line_dict[\"drug_name\"]\n",
    "        company = line_dict[\"company\"]\n",
    "        indication = line_dict[\"indication\"]\n",
    "        sales_unit = line_dict[\"sales_unit\"]\n",
    "        if indication != \"\":\n",
    "            if drug_name in drug_name_indication_dict:\n",
    "                drug_name_indication_dict[drug_name].add(indication)\n",
    "            else:\n",
    "                drug_name_indication_dict[drug_name] = set()\n",
    "                drug_name_indication_dict[drug_name].add(indication)\n",
    "        \n",
    "        drug_name_company = drug_name + \"####\" + company\n",
    "        drug_name_company_set.add(drug_name_company)\n",
    "        \n",
    "        drugname_company_sales_unit = drug_name + \"####\" + company + \"####\" + sales_unit\n",
    "        if drugname_company_sales_unit in drugname_company_sales_unit_dict:\n",
    "            drugname_company_sales_unit_dict[drugname_company_sales_unit].append(line_dict)\n",
    "        else:\n",
    "            drugname_company_sales_unit_dict[drugname_company_sales_unit] = []\n",
    "            drugname_company_sales_unit_dict[drugname_company_sales_unit].append(line_dict)\n",
    "    num = 0\n",
    "    fl.seek(0,0)\n",
    "    for line in fl:\n",
    "        num += 1\n",
    "#        if num > 500:\n",
    "#            break\n",
    "        line_dict = json.loads(line.strip())\n",
    "        drug_name = line_dict[\"drug_name\"]\n",
    "        company = line_dict[\"company\"]\n",
    "        sales_unit = line_dict[\"sales_unit\"]\n",
    "        drug_name_company_combine = drug_name + \"####\" + company\n",
    "        drugname_company_sales_unit_combine = drug_name + \"####\" + company + \"####\" + sales_unit\n",
    "        if drug_name not in drug_name_indication_dict:\n",
    "            fw2.write(json.dumps(line_dict) + \"\\n\")\n",
    "        else:\n",
    "            if company == \"\":\n",
    "                fw2.write(json.dumps(line_dict) + \"\\n\")\n",
    "            else:\n",
    "                if drug_name_company_combine not in drug_name_company_set:\n",
    "                    indication_list = drug_name_indication_dict[drug_name]\n",
    "                    for indication in indication_list:\n",
    "                        line_dict[\"indication\"] = indication\n",
    "                        fw1.write(json.dumps(line_dict) + \"\\n\")\n",
    "                else:\n",
    "                    if drugname_company_sales_unit_combine not in drugname_company_sales_unit_dict:\n",
    "                        indication_list = drug_name_indication_dict[drug_name]\n",
    "                        for indication in indication_list:\n",
    "                            line_dict[\"indication\"] = indication\n",
    "                            fw1.write(json.dumps(line_dict) + \"\\n\")\n",
    "                    else:\n",
    "#                        print(len(drugname_company_sales_unit_dict[drugname_company_sales_unit_combine]))\n",
    "                        if len(drugname_company_sales_unit_dict[drugname_company_sales_unit_combine]) >1:  #  人工处理这几条数据\n",
    "                            print(drugname_company_sales_unit_dict[drugname_company_sales_unit_combine])\n",
    "                            print(json.dumps(line_dict))\n",
    "                        else:\n",
    "                            sales_2014 = line_dict[\"2014_sales\"]\n",
    "                            sales_2015 = line_dict[\"2015_sales\"]\n",
    "                            sales_2016 = line_dict[\"2016_sales\"]\n",
    "                            sales_2017 = line_dict[\"2017_sales\"]\n",
    "                            sales_2018 = line_dict[\"2018_sales\"]\n",
    "#                             if sales_2014 == \"\":\n",
    "#                                 sales_2014 = \"0\"\n",
    "#                             if sales_2015 == \"\":\n",
    "#                                 sales_2015 = \"0\"\n",
    "#                             if sales_2016 == \"\":\n",
    "#                                 sales_2016 = \"0\"\n",
    "#                             if sales_2017 == \"\":\n",
    "#                                 sales_2017 = \"0\"\n",
    "#                             if sales_2018 == \"\":\n",
    "#                                 sales_2018 = \"0\"\n",
    "                            flag = 0\n",
    "                            if (sales_2014 != \"\") and (drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2014_sales\"] != \"\") \\\n",
    "                                and (sales_2014 != drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2014_sales\"]):\n",
    "                                flag =1\n",
    "                            if (sales_2015 != \"\") and (drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2015_sales\"] != \"\") \\\n",
    "                                and (sales_2015 != drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2015_sales\"]):\n",
    "                                flag = 1\n",
    "                            if (sales_2016 != \"\") and (drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2016_sales\"] != \"\") \\\n",
    "                                and (sales_2016 != drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2016_sales\"]):\n",
    "                                flag = 1\n",
    "                            if (sales_2017 != \"\") and (drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2017_sales\"] != \"\") \\\n",
    "                                and (sales_2017 != drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2017_sales\"]):\n",
    "                                flag = 1\n",
    "                            if (sales_2018 != \"\") and (drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2018_sales\"] != \"\") \\\n",
    "                                and (sales_2018 != drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2018_sales\"]):\n",
    "                                flag = 1\n",
    "                            if flag == 1:\n",
    "                                fw1.write(json.dumps(line_dict) + \"\\n\")\n",
    "                            else:\n",
    "                                if drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2014_sales\"] == \"\":\n",
    "                                    sales_2014_new = sales_2014\n",
    "                                    drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2014_sales\"] = sales_2014_new\n",
    "                                if drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2015_sales\"] == \"\":\n",
    "                                    sales_2015_new = sales_2015\n",
    "                                    drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2015_sales\"] = sales_2015_new\n",
    "                                if drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2016_sales\"] == \"\":\n",
    "                                    sales_2016_new = sales_2016\n",
    "                                    drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2016_sales\"] = sales_2016_new\n",
    "                                if drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2017_sales\"] == \"\":\n",
    "                                    sales_2017_new = sales_2017\n",
    "                                    drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2017_sales\"] = sales_2017_new\n",
    "                                if drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2018_sales\"] == \"\":\n",
    "                                    sales_2018_new = sales_2018\n",
    "                                    drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"2018_sales\"] = sales_2018_new\n",
    "                                drugname_company_sales_unit_dict[drugname_company_sales_unit_combine][0][\"source\"].append(\"pharmcube\")\n",
    "                                \n",
    "    for key,value_list in drugname_company_sales_unit_dict.items():\n",
    "        for value in value_list:\n",
    "            fw1.write(json.dumps(value) + \"\\n\")\n",
    "        \n",
    "                        \n",
    "\n",
    "\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "02030\n"
     ]
    }
   ],
   "source": [
    "sales = \"23\"\n",
    "sales_replace = sales.replace(\"\",\"0\")\n",
    "print(sales_replace)\n",
    "#print(int(sales.replace(\"\",\"0\")))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "38398\n"
     ]
    }
   ],
   "source": [
    "print(len(drugname_company_sales_unit_dict))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'drug_name': 'somavert', 'indication': 'acromegaly', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'somavert', 'indication': 'radiation therapy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'somavert', 'indication': 'acromegaly', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'signifor', 'indication': 'acromegaly, pituitary acth hypersecretion', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'angiox', 'indication': 'acute coronary syndrome', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndrome, angina, unstable, myocardial infarction', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'prasugrel hydrochloride', 'indication': 'unstable angina', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'cardiovascular diseases', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'heart diseases', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'diabetes mellitus', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary artery disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndrome', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndrome', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary arteriosclerosis', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndromes', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'platelet inhibition', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary stent implantation', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'sickle cell anemia', 'phase_front_display': 'phase 2'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'heart disease', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'ischemic heart disease', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'st-elevation myocardial infarction', 'phase_front_display': 'not applicable'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndromes', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary artery disease', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'healthy volunteers', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'sepsis', 'phase_front_display': 'approved'}, {'phase': 'phase 1', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'healthy', 'phase_front_display': 'phase 1'}, {'phase': 'phase 3', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'st-segment elevation myocardial infarction', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndrome', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary artery disease', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'myocardial infarction', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary artery bypass', 'phase_front_display': 'phase 3'}, {'phase': 'phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'anemia, sickle cell', 'phase_front_display': 'phase 1'}, {'phase': 'phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'adverse effect of antithrombotic drugs', 'phase_front_display': 'phase 1'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'unstable angina', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndrome', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary arteriosclerosis', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'myocardial ischemia', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'cardiovascular diseases', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'sickle cell disease', 'phase_front_display': 'phase 3'}, {'phase': 'phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'healthy volunteers', 'phase_front_display': 'phase 1'}, {'phase': 'phase 4', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary artery disease', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'st-elevation myocardial infarction', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'primary percutaneous coronary intervention', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'myocardial infarction', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'stemi', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'diabetes mellitus', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary artery disease', 'phase_front_display': 'not applicable'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'cardiovascular disease', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndrome', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary artery disease', 'phase_front_display': 'phase 3'}, {'phase': 'phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'coronary artery disease', 'phase_front_display': 'phase 1'}, {'phase': 'phase 2phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'stable coronary artery disease', 'phase_front_display': 'phase 2phase 3'}, {'phase': 'phase 2phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndrome', 'phase_front_display': 'phase 2phase 3'}, {'phase': 'phase 2phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'percutaneous coronary intervention', 'phase_front_display': 'phase 2phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'myocardial infarction', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'myocardial infarction', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'angioplasty, balloon, coronary', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'platelet aggregation inhibitors', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute myocardial infarction', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'cardiovascular diseases', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'acute coronary syndrome', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'sickle cell disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'cardiovascular disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'prasugrel hydrochloride', 'indication': 'atrial fibrillation', 'phase_front_display': 'phase 3'}]\n",
      "[{'drug_name': 'duoplavin', 'indication': 'acute coronary syndrome, myocardial infarction', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'clopidogrel/acetylsalicylic acid zentiva (previously duocover)', 'indication': 'acute coronary syndrome, myocardial infarction', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'clopidogrel/acetylsalicylic acid teva', 'indication': 'acute coronary syndrome, myocardial infarction', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'clopidogrel teva (hydrogen sulphate)', 'indication': 'acute coronary syndrome, peripheral vascular diseases, myocardial infarction, stroke', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'kengrexal', 'indication': 'acute coronary syndrome, vascular surgical procedures', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'onsenal', 'indication': 'adenomatous polyposis coli', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'lysodren', 'indication': 'adrenal cortex neoplasms', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'alkindi', 'indication': 'adrenal insufficiency', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'plenadren', 'indication': 'adrenal insufficiency', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'selincro', 'indication': 'alcohol-related disorders', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'lamzede', 'indication': 'alpha-mannosidosis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'memantine mylan', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'memantine accord', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ebixa', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'nemdatine', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'memantine ratiopharm', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'axura', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'marixino (previously maruxa)', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'memantine lek', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'memantine merz', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'rivastigmine 3m health care ltd', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'acrescent', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'balaxur', 'indication': 'alzheimer disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'rivastigmine 1 a pharma', 'indication': 'alzheimer disease, dementia, parkinson disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'prometax', 'indication': 'alzheimer disease, parkinson disease, dementia', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'carbaglu', 'indication': 'amino acid metabolism, inborn errors, propionic acidemia', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'tegsedi', 'indication': 'amyloidosis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'tegsedi', 'indication': 'polyneuropathy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'vyndaqel', 'indication': 'amyloidosis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'onpattro', 'indication': 'amyloidosis, familial', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'onpattro', 'indication': 'polyneuropathy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'rilutek', 'indication': 'amyotrophic lateral sclerosis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'riluzole zentiva', 'indication': 'amyotrophic lateral sclerosis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'alsitek', 'indication': 'amyotrophic lateral sclerosis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'silapo', 'indication': 'anemia, blood transfusion, autologous, cancer, kidney failure, chronic', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'retacrit', 'indication': 'anemia, blood transfusion, autologous, kidney failure, chronic, cancer', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'retacrit', 'indication': 'chronic kidney disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'aranesp', 'indication': 'anemia, cancer, kidney failure, chronic', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'feraccru', 'indication': 'anemia, iron-deficiency', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'mircera', 'indication': 'anemia, kidney failure, chronic', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'mircera', 'indication': 'chronic kidney disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'mircera', 'indication': 'ckd', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'epoetin alfa', 'indication': 'anemia, kidney failure, chronic', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'epoetin alfa', 'indication': 'anemia, kidney failure, chronic, cancer', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ttd'], 'phase_front_display': ''}, {'drug_name': 'epoetin alfa', 'indication': 'chronic kidney disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'phase': 'phase 2', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia, iron deficiency', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia of chronic disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'hip arthropathy', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'knee arthropathy', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'breast cancer', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'neoplasm metastasis', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'renal failure , chronic', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 2'}, {'phase': '', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'red-cell aplasia, pure', 'phase_front_display': ''}, {'phase': '', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic renal failure', 'phase_front_display': ''}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 3'}, {'phase': '', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': ''}, {'phase': '', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'neoplasms', 'phase_front_display': ''}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'cervical adenocarcinoma', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'cervical adenosquamous carcinoma', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'cervical squamous cell carcinoma', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'drug toxicity', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'radiation toxicity', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'stage iib cervical cancer', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'stage iii cervical cancer', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'stage iva cervical cancer', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'renal diseases', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'ischemia-reperfusion injury', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'myocardial infarction', 'phase_front_display': 'not applicable'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'congenital heart disease', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'hypoplastic left heart syndrome', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'transposition of the great arteries', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'aortic arch hypoplasia or interruption', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'pancreatic cancer', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'lung cancer', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic renal insufficiency', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'hemostasis, surgical', 'phase_front_display': 'approved'}, {'phase': 'phase 2', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'hiv infections', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'neuropathy', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'myocardial infarction', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'nephrology', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'type 1 diabetes', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'hypoglycemia', 'phase_front_display': 'not applicable'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'leukemia', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'lymphoma', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'lymphoproliferative disorder', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'multiple myeloma and plasma cell neoplasm', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'precancerous/nonmalignant condition', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'unspecified adult solid tumor, protocol specific', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'acute myelogenous leukemia', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'myelodysplastic syndrome', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'multiple myeloma', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'plasma cell neoplasm', 'phase_front_display': 'not applicable'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic kidney disease', 'phase_front_display': 'approved'}, {'phase': 'phase 2', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'cancer', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'subarachnoid hemorrhage', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic renal insufficiency', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'myelodysplastic syndromes', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'approved'}, {'phase': 'phase 2', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'peripheral neuropathy, chemotherapy-induced', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'mood disorders', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic kidney disease', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic kidney disease', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'head and neck cancer', 'phase_front_display': 'phase 3'}, {'phase': 'phase 1', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'lymphoma', 'phase_front_display': 'phase 1'}, {'phase': 'phase 1', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'neutropenia', 'phase_front_display': 'phase 1'}, {'phase': '', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic kidney disease', 'phase_front_display': ''}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'end stage renal disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'neoplasms', 'phase_front_display': 'approved'}, {'phase': 'phase 2', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'neonatal anemia', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'preterm infants', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'renal insufficiency, chronic', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'renal dialysis', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'erythrocyte transfusion', 'phase_front_display': 'approved'}, {'phase': '', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'end-stage renal disease', 'phase_front_display': ''}, {'phase': '', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anaemia', 'phase_front_display': ''}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'osteoarthritis', 'phase_front_display': 'approved'}, {'phase': 'phase 1', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'healthy', 'phase_front_display': 'phase 1'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'traumatic brain injury', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'not applicable'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic renal failure', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'traumatic brain injury', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia in end stage renal disease', 'phase_front_display': 'phase 2'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'leukemia', 'phase_front_display': 'not applicable'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia in incident dialysis patients', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic kidney disease', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'friedreich ataxia', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'traumatic brain injury', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'antineoplastic chemotherapy induced anemia', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'myelodysplastic syndromes', 'phase_front_display': 'phase 3'}, {'phase': 'phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'chronic renal failure', 'phase_front_display': 'phase 1'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'heart; dysfunction postoperative, cardiac surgery', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia, iron-deficiency', 'phase_front_display': 'approved'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'hypoxic-ischemic encephalopathy', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'neonatal encephalopathy', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'birth asphyxia', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'end stage renal disease (esrd)', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anaemia', 'phase_front_display': 'phase 2'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'cardiac surgery-cabg and/or cardiac valve replacement', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anaemia', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'ckd anemia in stable dialysis patients', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'end stage renal disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'ect', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'cognitive impairment', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'unipolar depression', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'bipolar depression', 'phase_front_display': 'phase 2'}, {'phase': 'not applicable', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'allogenic transfusion', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'perioperative anaemia', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'knee arthroplasty', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'hip arthroplasty', 'phase_front_display': 'not applicable'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'bipolar disorder', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'cyanotic congenital heart disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'anemia', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'cyanosis', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'congenital heart disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'myelodysplastic syndromes', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'dialysis-dependent chronic kidney disease', 'phase_front_display': 'phase 2'}, {'phase': 'phase 1', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'epoetin alfa', 'indication': 'sports drug abuse', 'phase_front_display': 'phase 1'}]\n",
      "[{'drug_name': 'rienso', 'indication': 'anemia, kidney failure, chronic', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'abseamed', 'indication': 'anemia, kidney failure, chronic, cancer', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'xromi', 'indication': 'anemia, sickle cell', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'siklos', 'indication': 'anemia, sickle cell', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ranexa (previously latixa)', 'indication': 'angina pectoris', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'corlentor', 'indication': 'angina pectoris, heart failure', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'procoralan', 'indication': 'angina pectoris, heart failure', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ivabradine accord', 'indication': 'angina pectoris, heart failure', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ivabradine anpharm', 'indication': 'angina pectoris, heart failure', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ivabradine jensonr', 'indication': 'angina pectoris, heart failure', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ivabradine zentiva', 'indication': 'angina pectoris, heart failure', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'integrilin', 'indication': 'angina, unstable, myocardial infarction', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'rhucin', 'indication': 'angioedema', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'rhucin', 'indication': 'hereditary angioedema', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ttd'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'firazyr', 'indication': 'angioedemas, hereditary', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'takhzyro', 'indication': 'angioedemas, hereditary', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ruconest', 'indication': 'angioedemas, hereditary', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'cinryze', 'indication': 'angioedemas, hereditary', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'cinryze', 'indication': 'hereditary angioedema', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ttd'], 'phase_front_display': ''}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'cinryze', 'indication': 'hereditary angioedema', 'phase_front_display': 'approved'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'cinryze', 'indication': 'hereditary angioedema', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'cinryze', 'indication': 'hereditary angioedema (hae)', 'phase_front_display': 'phase 3'}, {'phase': 'phase 1', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'cinryze', 'indication': 'kidney failure', 'phase_front_display': 'phase 1'}]\n",
      "[{'drug_name': 'bemfola', 'indication': 'anovulation', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ovaleap', 'indication': 'anovulation', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'rekovelle', 'indication': 'anovulation', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'ovitrelle', 'indication': 'anovulation, reproductive techniques, assisted, infertility, female', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'gonal-f', 'indication': 'anovulation, reproductive techniques, assisted, infertility, female, hypogonadism', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'atryn', 'indication': 'antithrombin iii deficiency', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'xeristar', 'indication': 'anxiety disorders, depressive disorder, major, diabetic neuropathies', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'duloxetine zentiva', 'indication': 'anxiety disorders, depressive disorder, major, neuralgia, diabetes mellitus', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'duloxetine hydrochloride', 'indication': 'anxiety disorders, diabetic neuropathies, depressive disorder, major', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'generalized anxiety disorder', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'diabetic peripheral neuropathic pain', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'anxiety', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'depressed mood', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'irritability', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'low back pain', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'suicide attempt', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'restlessnes', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'psychomotor agitation', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'osteoarthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'worry', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'duloxetine hydrochloride', 'indication': 'anxiety disorder', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'phase': 'phase 2phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'fatigue syndrome, chronic', 'phase_front_display': 'phase 2phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'peripheral neuropathy', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'neuropathic pain', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'alcohol dependence', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'back pain without radiation', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'diabetic neuropathies', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'worry', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'anxiety', 'phase_front_display': 'not applicable'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'generalized anxiety disorder', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'multiple sclerosis', 'phase_front_display': 'phase 2phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depression', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'bereavement', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'major depressive disorder', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'idiopathic parkinson disease', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'anxiety disorder', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'binge eating', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depression', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'diabetic neuropathy, painful', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'osteoarthritis knee pain', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depression', 'phase_front_display': 'not applicable'}, {'phase': 'phase 3', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'posttraumatic stress disorders', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'suspended', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depression', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'major depressive disorder', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'neurotoxicity', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'pain', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'peripheral neuropathy', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'unspecified adult solid tumor, protocol specific', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'attention deficit disorder with hyperactivity', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'withdrawn', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'painful diabetic neuropathy', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'chronic low back pain', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'major depressive disorder', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'multiple sclerosis', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'fibromyalgia', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'major depressive disorder (mdd)', 'phase_front_display': 'approved'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depression', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'pelvis pain chronic', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'healthy controls', 'phase_front_display': 'approved'}, {'phase': 'not applicable', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'fibromyalgia', 'phase_front_display': 'not applicable'}, {'phase': 'phase 2', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depressive disorder, major', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'generalized anxiety disorder', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'back pain lower back chronic', 'phase_front_display': 'phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'gulf war illness', 'phase_front_display': 'phase 2'}, {'phase': 'early phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'stroke', 'phase_front_display': 'early phase 1'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'diabetic neuropathy, painful', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'fibromyalgia, primary', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'fibromyalgia, secondary', 'phase_front_display': 'approved'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'systemic lupus erythematosus', 'phase_front_display': 'not applicable'}, {'phase': 'phase 3', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'major depressive disorder', 'phase_front_display': 'phase 3'}, {'phase': 'phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'mood disorder', 'phase_front_display': 'phase 1'}, {'phase': 'phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'substance-related disorders', 'phase_front_display': 'phase 1'}, {'phase': 'phase 1', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'amphetamine-related disorders', 'phase_front_display': 'phase 1'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'osteoarthritis', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'temporomandibular joint disorders', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'major depressive disorder', 'phase_front_display': 'not applicable'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'schizophrenia', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'anxiety neuroses', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'anxiety states, neurotic', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'neuroses, anxiety', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'osteoarthritis', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'chronic pain', 'phase_front_display': 'approved'}, {'phase': 'phase 3', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'breast cancer', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'musculoskeletal complications', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'pain', 'phase_front_display': 'phase 3'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'healthy participants', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'fibromyalgia', 'phase_front_display': 'approved'}, {'phase': 'phase 2', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'traumatic brain injury', 'phase_front_display': 'phase 2'}, {'phase': 'phase 2', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depression', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'major depression', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'irritable bowel syndrome', 'phase_front_display': 'approved'}, {'phase': 'phase 2phase 3', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'postoperative myalgia', 'phase_front_display': 'phase 2phase 3'}, {'phase': 'phase 2', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'low back pain', 'phase_front_display': 'phase 2'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'diabetic peripheral neuropathic pain', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'quality of recovery', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'gynecologic surgery', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'laparoscopy', 'phase_front_display': 'approved'}, {'phase': '', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'anxiety disorders', 'phase_front_display': ''}, {'phase': '', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'panic disorder', 'phase_front_display': ''}, {'phase': '', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'obsessive-compulsive disorder', 'phase_front_display': ''}, {'phase': '', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'post-traumatic stress disorder', 'phase_front_display': ''}, {'phase': '', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'generalized anxiety disorder', 'phase_front_display': ''}, {'phase': '', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'social anxiety disorder', 'phase_front_display': ''}, {'phase': 'phase 2', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'neuropathic pain', 'phase_front_display': 'phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depressive disorder', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'terminated', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'depression', 'phase_front_display': 'phase 3'}, {'phase': 'phase 1phase 2', 'recruitment_status': 'active, not recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'osteoarthritis of knee', 'phase_front_display': 'phase 1phase 2'}, {'phase': 'phase 3', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'major depressive disorder', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'prostate cancer', 'phase_front_display': 'phase 3'}, {'phase': 'phase 3', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'urinary incontinence', 'phase_front_display': 'phase 3'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'pain', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'osteoarthritis', 'phase_front_display': 'not applicable'}, {'phase': 'phase 4', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'mild cognitive impairment', 'phase_front_display': 'approved'}, {'phase': 'not applicable', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'pain management', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'cancer pain', 'phase_front_display': 'not applicable'}, {'phase': 'phase 4', 'recruitment_status': 'enrolling by invitation', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'joint disease', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'enrolling by invitation', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'pain, acute', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'enrolling by invitation', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'pain, chronic', 'phase_front_display': 'approved'}, {'phase': 'phase 4', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'intervertebral disc degeneration', 'phase_front_display': 'approved'}, {'phase': 'not applicable', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'fibromyalgia', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'hyperbaric oxygen', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'unknown status', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'osteoarthritis', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'laparoscopic hysterectomy', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'postoperative recovery', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'completed', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'postoperative pain', 'phase_front_display': 'not applicable'}, {'phase': 'not applicable', 'recruitment_status': 'not yet recruiting', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['clinicaltrails'], 'drug_name': 'duloxetine hydrochloride', 'indication': 'chronic pain', 'phase_front_display': 'not applicable'}]\n",
      "[{'drug_name': 'pregabalin pfizer', 'indication': 'anxiety disorders, epilepsy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'pregabalin mylan', 'indication': 'anxiety disorders, epilepsy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'pregabalin accord', 'indication': 'anxiety disorders, epilepsy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'pregabalin zentiva', 'indication': 'anxiety disorders, epilepsy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'pregabalin sandoz gmbh', 'indication': 'anxiety disorders, epilepsy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'pregabalin mylan pharma', 'indication': 'anxiety disorders, neuralgia, epilepsy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'pregabalin zentiva k.s.', 'indication': 'anxiety disorders, neuralgia, epilepsy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'pregabalin sandoz', 'indication': 'anxiety disorders, neuralgia, epilepsy', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'peyona (previously nymusa)', 'indication': 'apnea', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'orencia', 'indication': 'arthritis, psoriatic, arthritis, juvenile rheumatoid, arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'benepali', 'indication': 'arthritis, psoriatic, arthritis, rheumatoid, psoriasis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'amgevita', 'indication': 'arthritis, psoriatic, colitis, ulcerative, arthritis, juvenile rheumatoid, spondylitis, ankylosing, psoriasis, crohn disease, arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'jylamvo', 'indication': 'arthritis, psoriatic, precursor cell lymphoblastic leukemia-lymphoma, psoriasis, arthritis, rheumatoid, arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'otezla', 'indication': 'arthritis, psoriatic, psoriasis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'nordimet', 'indication': 'arthritis, psoriatic, psoriasis, arthritis, juvenile rheumatoid, arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'erelzi', 'indication': 'arthritis, psoriatic, psoriasis, arthritis, juvenile rheumatoid, arthritis, rheumatoid, spondylitis, ankylosing', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'zessly', 'indication': 'arthritis, psoriatic, psoriasis, crohn disease, arthritis, rheumatoid, colitis, ulcerative, spondylitis, ankylosing', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'cosentyx', 'indication': 'arthritis, psoriatic, psoriasis, spondylitis, ankylosing', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'simponi', 'indication': 'arthritis, psoriatic, spondylitis, ankylosing, colitis, ulcerative, arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'inflectra', 'indication': 'arthritis, psoriatic, spondylitis, ankylosing, colitis, ulcerative, psoriasis, crohn disease, arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'inflectra', 'indication': 'rectovaginal fistula', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'inflectra', 'indication': 'psoriatic arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'inflectra', 'indication': 'arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'inflectra', 'indication': 'rheumatoid arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'inflectra', 'indication': 'ulcerative colitis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'remsima', 'indication': 'arthritis, psoriatic, spondylitis, ankylosing, colitis, ulcerative, psoriasis, crohn disease, arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'solymbic', 'indication': 'arthritis, psoriatic, spondylitis, ankylosing, crohn disease, colitis, ulcerative, hidradenitis suppurativa, psoriasis, arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'lifmior', 'indication': 'arthritis, psoriatic, spondylitis, ankylosing, psoriasis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'cimzia', 'indication': 'arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'cimzia', 'indication': 'crohn disease', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'cimzia', 'indication': 'active rheumatoid arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'cimzia', 'indication': 'psoriatic arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'cimzia', 'indication': 'rheumatoid arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'xeljanz', 'indication': 'arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'kevzara', 'indication': 'arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'interleukin 1 receptor antagonist protein', 'indication': 'arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'interleukin 1 receptor antagonist protein', 'indication': 'active rheumatoid arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}, {'drug_name': 'interleukin 1 receptor antagonist protein', 'indication': 'interleukin-1 receptor antagonist', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'olumiant', 'indication': 'arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}, {'drug_name': 'olumiant', 'indication': 'rheumatoid arthritis', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['fda'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'leflunomide ratiopharm', 'indication': 'arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'leflunomide medac', 'indication': 'arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'leflunomide teva', 'indication': 'arthritis, rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n",
      "[{'drug_name': 'roactemra', 'indication': 'arthritis, rheumatoid, arthritis, juvenile rheumatoid', 'phase': '', 'recruitment_status': '', 'company': '', '2014_sales': '', '2015_sales': '', '2016_sales': '', '2017_sales': '', '2018_sales': '', 'sales_unit': 'million usd', 'source': ['ema'], 'phase_front_display': ''}]\n"
     ]
    }
   ],
   "source": [
    "num = 0\n",
    "for key,value_list in drugname_company_sales_unit_dict.items():\n",
    "    num += 1\n",
    "    if num > 100:\n",
    "        break\n",
    "    else:\n",
    "        print(value_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
